---
title: 'Chem-CRISPR/dCas9FCPF: a platform for chemically induced epigenome editing'
date: '2024-09-24'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39315698/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20240924183559&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: Epigenetic aberration is one of the major driving factors in human cancer,
  often leading to acquired resistance to chemotherapies. Various small molecule epigenetic
  modulators have been reported. Nonetheless, outcomes from animal models and clinical
  trials have underscored the substantial setbacks attributed to pronounced on- and
  off-target toxicities. To address these challenges, CRISPR/dCas9 technology is emerging
  as a potent tool for precise modulation of epigenetic mechanism. However, ...
disable_comments: true
---
Epigenetic aberration is one of the major driving factors in human cancer, often leading to acquired resistance to chemotherapies. Various small molecule epigenetic modulators have been reported. Nonetheless, outcomes from animal models and clinical trials have underscored the substantial setbacks attributed to pronounced on- and off-target toxicities. To address these challenges, CRISPR/dCas9 technology is emerging as a potent tool for precise modulation of epigenetic mechanism. However, ...